Prospects for a safe COVID-19 vaccine

被引：174

作者：

Haynes, Barton F. ^{[1
]}

Corey, Lawrence ^{[2
]}

Fernandes, Prabhavathi ^{[3
]}

Gilbert, Peter B. ^{[4
]}

Hotez, Peter J. ^{[5
]}

Rao, Srinivas ^{[6
]}

Santos, Michael R. ^{[7
]}

Schuitemaker, Hanneke ^{[8
]}

Watson, Michael ^{[9
]}

Arvin, Ann ^{[10
,11
]}

机构：

[1] Duke Univ, Duke Human Vaccine Inst, Sch Med, Durham, NC 27710 USA

[2] Univ Washington, Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA

[3] Global Antibiot Res & Dev Partnership GARDP, Geneva, Switzerland

[4] Fred Hutchinson Canc Res, Vaccine & Infect Dis Div, Seattle, WA 98109 USA

[5] Baylor Coll Med, Texas Childrens Ctr Vaccine Dev, Natl Sch Trop Med, Houston, TX 77030 USA

[6] Sanofi, Sanofi Res & Dev, Cambridge, MA 02139 USA

[7] Fdn Natl Inst Hlth, North Bethesda, MD 20852 USA

[8] Janssen Vaccines & Prevent BV, Leiden, Netherlands

[9] Moderna Inc, Cambridge, MA 02139 USA

[10] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA

[11] Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA

来源：

SCIENCE TRANSLATIONAL MEDICINE | 2020年 / 12卷 / 568期

基金：

美国国家卫生研究院;

关键词：

ACUTE RESPIRATORY SYNDROME; SYNCYTIAL VIRUS-DISEASE; SYNDROME CORONAVIRUS INFECTION; T-CELL RESPONSES; SARS CORONAVIRUS; NEUTRALIZING ANTIBODY; SEROLOGIC RESPONSES; PROTECTIVE IMMUNITY; COTTON RATS; VIRAL LOAD;

D O I：

10.1126/scitranslmed.abe0948

中图分类号：

Q2 [细胞生物学];

学科分类号：

071013 [干细胞生物学];

摘要：

Rapid development of an efficacious vaccine against the viral pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and postlicensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, after vaccination.

引用

页数：12

共 114 条

[1]

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus [J].